Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Abstract: Inflammatory bowel disease (IBD) is a problem that directly affects the quality of life of patients suffering from this condition. Monitoring the serum level of infliximab (IFX) (TDM) is an important tool for guiding therapeutic decisions in IBD patients. The purpose of this study was to determine the significance of quantitatively measuring the serum level of IFX (TDM) and antibody to IFX (ATI). Methods and materials: Prospective observational study involving 40 IBD patients on IFX therapy, including 14 Proactive (week 06 of the induction phase) and 26 Reactive (maintenance phase). Immediately prior to the infusion, blood samples were drawn and measured using a Bulhlmann rapid test instrument. Serum concentrations of IFX were categorized as supratherapeutic (>7.0 micrograms/ml), therapeutic (between 3.0 and 7.0 micrograms/ml), and subtherapeutic (3.0 micrograms/ml). When the serum concentration of IFX was 3 mcg/ml (subtherapeutic), the ATI was measured. 25 patients with CD and 15 patients with UC were evaluated. Only three of the twenty patients with subtherapeutic serum levels had a positive ATI, and both were reactive; two had CD and one had UC. There was a statistically significant difference between reactive and proactive patients with respect to levels of CRP (p = 0.042), with proactive DNS patients suffering greater alterations in CRP and albumin.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Therapeutic Drug Monitoring in Inflammatory Bowel Disease ; volume:43 ; number:04 ; year:2023 ; pages:e276-e279
Journal of coloproctology ; 43, Heft 04 (2023), e276-e279
- Contributor
-
Neto, Manoel Alvaro de Freitas Lins
Rolim, João Otávio Moraes
Jatobá, Diogo César Maurício de Oliveira
de Meira, Júnia Elisa Carvalho
Filho, Luís Henrique Salvador
Lins, Lucas Correia
Peçanha, Jorge Artur Coelho
- DOI
-
10.1055/s-0043-1776892
- URN
-
urn:nbn:de:101:1-2024011111115715332222
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Neto, Manoel Alvaro de Freitas Lins
- Rolim, João Otávio Moraes
- Jatobá, Diogo César Maurício de Oliveira
- de Meira, Júnia Elisa Carvalho
- Filho, Luís Henrique Salvador
- Lins, Lucas Correia
- Peçanha, Jorge Artur Coelho
Other Objects (12)
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
Metabolism – New Therapeutic Targets for Inflammatory Bowel Disease
The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease
From therapeutic drug monitoring to total drug monitoring and drug-omics
Toxicology, including therapeutic drug monitoring
Therapeutic drug monitoring: linezolid too?
On-site therapeutic drug monitoring
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
Metabolism – New Therapeutic Targets for Inflammatory Bowel Disease
The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease
From therapeutic drug monitoring to total drug monitoring and drug-omics
Toxicology, including therapeutic drug monitoring
Therapeutic drug monitoring: linezolid too?
On-site therapeutic drug monitoring
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD
Therapeutic drug monitoring of oral targeted antineoplastic drugs
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical Results
Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
Metabolism – New Therapeutic Targets for Inflammatory Bowel Disease
The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease
From therapeutic drug monitoring to total drug monitoring and drug-omics
Toxicology, including therapeutic drug monitoring
Therapeutic drug monitoring: linezolid too?
On-site therapeutic drug monitoring
Biosensor-based monitoring of TNF antagonists and anti-drug antibodies in inflammatory bowel disease
Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD